Environmental

Low Direct Environmental Footprint: As a clinical-stage biopharmaceutical company, Milestone Pharmaceuticals has a limited direct environmental impact compared to manufacturing-based peers, with no evidence of large-scale production or significant emissions reported in recent filings or press releases.

Product Lifecycle and Sustainability: The company’s lead product, etripamil, is a nasal spray, which may present lower environmental risks in terms of hazardous waste or complex supply chains relative to injectable or biologic therapies, but there is no disclosed sustainability strategy for packaging or end-of-life product management.

Lack of Formal Environmental Policies: There is no evidence of published environmental targets, sustainability reporting, or climate risk disclosures, which is a gap versus best-in-class biopharma peers.

Milestone’s environmental risks are inherently limited by its business model, but the absence of formal sustainability policies or disclosures places it below sector leaders on environmental transparency and proactive management.

Social

Focus on Unmet Medical Needs: Milestone’s core mission is to address significant unmet needs in cardiovascular health, with clinical data supporting the efficacy and safety of etripamil for PSVT, which could improve patient quality of life and reduce emergency room visits if approved.

Talent Attraction and Retention: The company uses equity inducement plans to attract and retain key talent, aligning with industry norms, but high stock-based compensation (nearly 50% of revenue) and ongoing net losses may challenge long-term workforce stability.

Clinical Trial Safety and Patient Outcomes: Recent clinical trials report strong safety and tolerability for etripamil, with low rates of adverse events, supporting a positive patient impact and responsible clinical practices.

Milestone demonstrates a clear social mission and responsible clinical practices, but financial constraints and high reliance on equity-based compensation may limit its ability to sustain and scale positive social outcomes relative to larger, more established peers.

Governance

Board Oversight and Compliance: Equity awards and inducement grants are approved by the Board and Compensation Committee, and the company complies with Nasdaq Listing Rule 5635(c)(4), indicating adherence to governance standards for executive compensation and talent recruitment.

Financial Discipline and Capital Structure: Milestone maintains a high debt-to-equity ratio (2.79), but net debt to EBITDA is negative, reflecting a net cash position; however, persistent net losses and negative gross margins highlight ongoing financial risk and the need for careful capital allocation.

Regulatory Engagement and Transparency: The company provides regular updates on regulatory milestones, clinical progress, and financial status, supporting transparency, but lacks detailed ESG or risk disclosures in public filings.

Milestone’s governance practices meet basic compliance and transparency standards, but financial risk and limited ESG-specific disclosures constrain its governance score relative to best-in-class biopharma peers.

Overall Score

Milestone Pharmaceuticals demonstrates moderate ESG performance, with limited environmental risk, a strong social mission, and basic governance compliance. However, the absence of formal ESG policies, persistent financial losses, and limited transparency on sustainability and risk management keep its overall ESG profile below sector leaders.